Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ozekibart (INBRX-109)
i
Other names:
INBRX-109, INBRX 109, JCT-205, INBRX109, JCT205, JCT 205
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Inhibrx Biosci, Transcenta
Drug class:
TRAIL R2 agonist
Related drugs:
‹
ABBV-621 (3)
AMG 655 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
ONKT101 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
ABBV-621 (3)
AMG 655 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
ONKT101 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Sarcoma
No biomarker
Sarcoma
INBRX-109
Sensitive: B - Late Trials
INBRX-109
Sensitive
:
B
INBRX-109
Sensitive: B - Late Trials
INBRX-109
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login